Welcome to our dedicated page for ALPHA COGNITION NEW news (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on ALPHA COGNITION NEW stock.
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases. The company is primarily focused on addressing conditions like Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), which currently lack approved treatment options.
Alpha Cognition's flagship product, ALPHA-1062, is a patented new chemical entity in development as a next-generation acetylcholinesterase inhibitor for the treatment of mild-to-moderate Alzheimer’s disease. Designed to minimize gastrointestinal side effects, ALPHA-1062's active metabolite is differentiated from existing therapies like donepezil and rivastigmine. The compound binds to neuronal nicotinic receptors, notably the alpha-7 subtype, which is known to positively affect cognition. ALPHA-1062 is also being developed in combination with memantine for moderate to severe Alzheimer’s dementia and as an intranasal formulation for Cognitive Impairment with mTBI.
In recent developments, Alpha Cognition has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALPHA-1062, with an expected approval date in the second half of 2024. This milestone underscores the company's commitment to advancing patient care and highlights their robust pipeline of innovative treatments.
Alpha Cognition has also received significant recognition in the form of patents and grants. The company was recently awarded a $750,000 research and development grant from the U.S. Department of Defense to study ALPHA-1062's potential in treating mTBI. Additionally, the company holds multiple patents for ALPHA-1062, including a new composition-of-matter patent that extends protection into 2044.
The company's financial strategy includes successfully raising gross proceeds of $8.45 million through private placements, which will be used for research and development, general and administrative matters, and working capital. This funding is crucial for furthering the development and potential commercialization of their lead product, ALPHA-1062.
Alpha Cognition's commercialization strategy aims to initially target the Long Term Care (LTC) market, followed by the broader Neurology segment once payer reimbursement is established. This approach is expected to maximize the impact of ALPHA-1062 in the Alzheimer’s treatment landscape.
Overall, Alpha Cognition Inc. is poised for a transformational year with significant advancements in their pipeline, financial health, and strategic positioning to bring innovative therapies to market for neurodegenerative diseases.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has announced the discovery of two promising therapeutic candidates, ALPHA-0702 and ALPHA-0802, which demonstrate positive preclinical results in targeting neurodegenerative disorders. Derived from full-length progranulin (PGRN), these GEM combinations showed efficacy in enhancing cell survival and reducing TDP-43 toxicity. The company plans further studies to validate these findings, highlighting a significant step in its mission to develop effective treatments for diseases such as ALS and FTD.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has announced the granting of stock options for directors to purchase up to 400,000 common shares at $0.64 CAD each. These options are valid for ten years, subject to vesting provisions. The company focuses on developing novel therapies for neurodegenerative disorders, notably Alzheimer's and ALS. Their lead candidate, ALPHA-1062, has shown promise in clinical trials with improved safety and tolerability. The firm is also advancing ALPHA-0602, which has received Orphan Drug Designation for treating neurodegenerative diseases.
Alpha Cognition Inc. (TSX-V: ACOG; OTCQB: ACOGF) reported its first-quarter 2022 financial results, highlighting a net loss of $2.7 million, a significant reduction from $12.2 million in Q1 2021. Research and development expenses increased to $1.8 million, reflecting advancements in clinical studies. The company announced positive preclinical data for ALPHA-1062 and ALPHA-0602, with expectations to file for FDA approval for ALPHA-1062 in Q2 2023 and a projected commercial launch by Q1 2024. Cash reserves stood at $9.1 million as of March 31, 2022.
Alpha Cognition Inc. (ACOGF) reported its financial results for Q4 and the full year ended December 31, 2021, highlighting a transformational phase for the company. They achieved positive pre-clinical results for ALPHA-1062 and ALPHA-0602, therapies aimed at neurodegenerative disorders. The company is set to release pivotal trial results for ALPHA-1062 in Q2 2022, which is crucial for its Alzheimer’s treatment approval. R&D expenses rose to $2.7 million in Q4 2021, contributing to a net loss of $3.2 million for the quarter, with cash reserves at $11.3 million.
Alpha Cognition Inc. (TSX-V: ACOG) announced the appointment of Don Kalkofen as Chief Financial Officer, replacing Jeremy Wright, who will remain as a consultant. Kalkofen has extensive experience in biotechnology finance, most recently as CFO at Protagonist Therapeutics (NASDAQ: PTGX), where he facilitated over $550 million in financing. He will lead Alpha Cognition's financial operations and support strategic growth. In conjunction with his appointment, Kalkofen received 450,000 stock options at $0.93 CAD. CEO Michael McFadden was also appointed to the board of directors.
Alpha Cognition Inc. (ACOGF) has announced encouraging preclinical results for its ALPHA-0602 ALS gene therapy program. The AAV-based therapy showed significant PGRN expression in motor neurons, reduction in cell death, and improved motor neuron health in both in vitro and in vivo models. Key outcomes include increased cerebrospinal fluid PGRN levels and persistent weight gain in treated TDP-43 transgenic mice. The company plans to advance clinical trials to further validate these findings, marking a critical milestone in addressing ALS treatment.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced positive histology data from its ALPHA-1062 Traumatic Brain Injury (TBI) program, demonstrating neuroprotective effects that preserved hippocampal structure and reduced neuronal cell loss. The study showed statistically significant improvements in cognitive functioning. The company plans to meet with the FDA to discuss clinical development, underscoring a significant unmet need for effective TBI therapies. ALPHA-1062 is being developed as a novel acetylcholinesterase inhibitor targeting Alzheimer's disease.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) is participating in key investor conferences throughout January 2022, including the LifeSci Advisors Conference and the JP Morgan Healthcare Conference. The company focuses on developing novel therapies for neurodegenerative diseases such as Alzheimer's and ALS. Its lead product, ALPHA-1062, shows promise as a safer treatment option with minimal side effects, while ALPHA-0602 has received Orphan Drug Designation. An updated investor presentation is available on their website.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced the resignation of Dr. Fred Sancilio as Director and President but he will continue as a consultant focusing on ALPHA-1062. Dr. Cedric O’Gorman will lead the patient tolerability trial for ALPHA-1062. The company is on track to submit a New Drug Application (NDA) for ALPHA-1062 in late 2022. Additionally, 2,340,000 stock options were granted to directors and officers at an exercise price of $1.12 CAD per share, expiring in December 2031.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced promising data from its ALPHA-1062 program for treating Traumatic Brain Injury (TBI). In preclinical studies, ALPHA-1062 significantly reduced functional deficits in TBI subjects, showing recovery comparable to uninjured animals. The treatment, started two hours post-injury and administered for 35 days, improved both motor and cognitive functions. Current estimates suggest nearly 3 million TBI cases annually in the U.S., highlighting the potential market for effective treatments.
FAQ
What is the current stock price of ALPHA COGNITION NEW (ACOGF)?
What is the market cap of ALPHA COGNITION NEW (ACOGF)?
What is Alpha Cognition Inc.?
What is ALPHA-1062?
What recent milestone has Alpha Cognition achieved?
What are the financial highlights for Alpha Cognition?
What is the commercialization strategy for ALPHA-1062?
What grants and patents has Alpha Cognition received?
How does ALPHA-1062 differ from other treatments?
What is the potential market size for ALPHA-1062?
What is the significance of the new composition-of-matter patent for ALPHA-1062?
Who is the CEO of Alpha Cognition?
